MedPageToday -- ORLANDO -- A second-line treatment for chronic myeloid leukemia with the Philadelphia chromosome continues to outpoint its predecessor, a researcher said here. The tyrosine kinase inhibitor, nilotinib (Tasigna), was shown to have more rapid and powerful effects over a year of treatment than imatinib (Gleevec) in the so-called ENESTnd trial, according to Timothy Hughes, MD, of the Royal Adelaide Hospital in Adelaide, Australia.
